BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology
BioMed X announces the extension of its collaboration with Merck in the research project RNA Splicing in Cancer. Merck has decided to acquire the IP rights in the project results and to continue the project for another year. The goal of the extension is to further validate novel potential drug targets based on these results.